CapsoVision (CV) Gross Margin (2024 - 2026)

CapsoVision (CV) posted Gross Margin of 49.87% for Q4 2025, down 7.81% sequentially from 54.1% in Q3 2025, and down 36.0% YoY from 77.93% in Q4 2024.

CapsoVision (CV) Gross Margin (2024 - 2026) Analysis & Trends

CapsoVision has reported Gross Margin for 2 years, with the latest figure at 49.87% in Q4 2025.

Quarterly Gross Margin fell 36.0% year-over-year to 49.87% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 52.12% (changed N/A YoY) and the FY2025 annual result came in at 52.92%, down 132.0% from the prior year.
Gross Margin eased to 49.87% in Q4 2025 per CV's latest filing, from 54.1% in the prior quarter.
Over five years, Gross Margin peaked at 56.0% in Q2 2024 and troughed at 49.87% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	57.71%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	68.27%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	65.35%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	70.71%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	77.46%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	63.44%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	41.17%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	47.38%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	45.84%
10	CapsoVision	295.13 Mn	286.05 Mn	1.87 Mn	51.36%

Download Data